The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Thomas Yip - H.C. Wainwright - Analyst
: This is Thomas Yip, asking a couple of questions for Ed. So first, as you earlier in the call, so with now 10 years of market exclusivity up to 2034, can
you also discuss how far out the sulopenem portfolio provide coverage for both in the US and maybe in the Europe as well?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 14, 2024 / 1:30PM, ITRM.OQ - Q3 2024 Iterum Therapeutics PLC Earnings Call
Question: Thomas Yip - H.C. Wainwright - Analyst
: Understood. And then can you perhaps discuss ORLYNVAH label as it was approved? Does it meet your internal expectations in terms of how broad
it is and also the restrictions anticipated?
Question: Thomas Yip - H.C. Wainwright - Analyst
: What I was asking was the ORLYNVAH label as it was approved. Just wonder, did they meet your internal expectations in terms of how broad it is?
And then also the restrictions anticipated?
Question: Thomas Yip - H.C. Wainwright - Analyst
: Got it. And then perhaps one last question from us. I wonder if you can discuss what's your impression so far on your discussions on the strategic
options to date?
Question: Thomas Yip - H.C. Wainwright - Analyst
: Yes.
Question: Thomas Yip - H.C. Wainwright - Analyst
: Okay. Got it. Thank you again for taking the questions, and looking forward to updates on your [strategic] options.
Question: Jason McCarthy - Maxim Group - Analyst
: Thanks for taking the questions. Just from a partnering or acquirer perspective, given that your -- the last Phase 3, it was only in the US, would they
need another trial in EU, China, Japan, or some other region to extend approvals ex US? Or is the data sufficient with what you have?
Question: Jason McCarthy - Maxim Group - Analyst
: And -- thank you, and just one more. For any potential partner or suitor or otherwise, you did have -- I know the trial missed and complicated and
surgical. But the data was still very good, kind of vary in a similar vein to the uncomplicated UTI. Do you think that would potentially make this
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 14, 2024 / 1:30PM, ITRM.OQ - Q3 2024 Iterum Therapeutics PLC Earnings Call
more attractive? Could they leverage that data and do just another study like you did to get approval for uUTI? Is that a part of the discussions that
you're having? Or is it just really they're interested potentially uncomplicated only?
Question: Thomas Yip - H.C. Wainwright - Analyst
: Got it. Thanks for taking the question.
| 
